Drug Trial Radar · NCT05941507
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Oct 5, 2023
Primary completion
Jan 2027
Study completion May 2027
Sponsor
- Lead sponsor
- LigaChem Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- AntibodyChem Biosciences, Inc.
- First posted
- Jul 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanced solid tumors refractory to standard of care, or for whom no standard of care exists. After the MTD and/or RP2D for single agent LCB84 is determined, dose escalation cohorts with select tumor types will be enrolled. Combination LCB84 and anti-PD-1 Ab will be evaluated in dose escalation after a minimum of 2 dose levels of single agent LCB84 have established DLT safety, to determine the MTD and/or RP2D of combination LCB84 and anti-PD-1 Ab, and to continue into dose expansion cohorts in select tumor types.
Conditions
- Advanced Solid Tumors
Interventions
LCB84Drug
TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug
Anti-PD-1 monoclonal antibodyDrug
anti-PD-1 Ab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1 and 2)Time frame: Up to 48 months
- Recommended Phase 2 Dose of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1)Time frame: Up to 24 months
- Objective Response Rate (Phase 2)Time frame: Up to 24 months
- Clinical Benefit Rate (Phase 2)Time frame: Up to 24 months
- Duration of Response (Phase 2)Time frame: Up to 24 months
- Time to Progression (Phase 2)Time frame: Up to 24 months
- Progression Free Survival (Phase 2)Time frame: Up to 24 months
- Overall Survival (Phase 2)Time frame: Up to 24 months
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Cedars Sinai Medical Center
Los Angeles, California · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Tennessee Oncology
Nashville, Tennessee · Not yet recruiting
Mary Crowley Cancer Research
Dallas, Texas · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Not yet recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.